Enhanced expression of Fas Ligand (FasL) in the lower airways of patients with fibrotic interstitial lung diseases (ILDs)

Folia Histochemica et Cytobiologica

Volumn 49, Issue 4, 2011, Pages 636-645

  Kopiński, Piotr ^a   Balicka Ślusarczyk, Barbara ^b   Dyczek, Andrzej ^b   Szpechciński, Adam ^c   Przybylski, Grzegorz ^a   Jarzemska, Agnieszka ^a   Wandtke, Tomasz ^a   Jankowski, Marek ^a   Iwaniec, Teresa ^b   Chorostowska Wynimko, Joanna ^c  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

Author keywords

Alveolar lymphocytes; Bronchoalveolar lavage; Fas Ligand; Interstitial lung diseases; Lung fibrosis

Indexed keywords

FAS LIGAND;

ADULT; ARTICLE; ASBESTOSIS; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG ALVEOLUS MACROPHAGE; LUNG FIBROSIS; LUNG LAVAGE; LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; NEUTROPHILIA; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SARCOIDOSIS; VITAL CAPACITY;

EID: 84856962487     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2011.0087     Document Type: Article

References (30)

1. Chávez-Galán L, Arenas-Del Angel MC et al. Cell death mechanisms induced by cytotoxic lymphocytes. Cell Mol Immunol. 2009;6:15-25.
2. Kavurma MM, Khachigian LM. Signaling and transcriptional control of Fas ligand gene expression. Cell Death Differ. 2003;10:36-44.
3. Ramaswamy M, Cleland SY, Cruz AC, Siegel RM. Many checkpoints on the road to cell death: regulation of Fas-FasL interactions and Fas signaling in peripheral immune responses. Results Probl Cell Differ. 2009;49:17-47.
4. Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity. 2009;30: 180-192.
5. Tanaka M, Suda T, Haze K et al. Fas ligand in human serum. Nature Med. 1996;2:319-322.
6. Suda T, Okazaki T, Naito Y et al. Expression of the Fas ligand in cells of T cell lineage. J Immunol. 1995;154:3806-3813.
7. Matute-Bello G, Liles CW, Steinberg KP et al. Soluble Fas ligand induces epithelial cell apoptosis in humans with acute lung injury (ARDS). J Immunol. 1999;163:2217-2225.
8. Hashimoto S, Kobayashi A, Kooguchi K et al. Upregulation of two death pathways of perforin/granzyme and FasL/Fas in septic acute respiratory distress syndrome. Am J Respir Crit Care Med. 2000;161:237-243.
9. Matute-Bello G, Winn RK, Jonas M et al. Fas (CD95) induces alveolar epithelial cell apoptosis in vivo. Implications for acute pulmonary inflammation. Am J Pathol. 2001;158: 153-161.
10. Albertine KH, Soulier MF, Wang Z et al. Fas and Fas ligand are upregulated in pulmonary edema fluid and lung tissue of patients with acute lung injury and the acute respiratory distress syndrome. Am J Pathol. 2002;161:1783-1796.
11. Chopra M, Reuben JS, Sharma AC. Acute lung injury: apoptosis and signaling mechanisms. Exp Biol Med. 2009;234:361-371.
12. Kuwano K, Miyazaki H, Hagimoto N et al. The involvement of Fas-Fas ligand pathway in fibrosing lung diseases. Am J Respir Cell Mol Biol. 1999;20:53-60.
13. Kuwano K, Kawasami M, Maeyama T et al. Soluble form of Fas and Fas ligand in BAL fluid from patients with pulmonary fibrosis and bronchiolitis obliterans organizing pneumonia. Chest. 2000;118:451-458.
14. Wesche-Soldato DE, Swan RZ, Chung CS, Ayala A. The apoptotic pathway as a therapeutic target in sepsis. Curr Drug Targets. 2007;8:493-500.
15. Bohana-Kashtan O, Civin CI. Fas ligand as a tool for immunosuppression and generation of immune tolerance. Stem Cells. 2004;22:908-924.
16. Uhal BD. Apoptosis in lung fibrosis and repair. Chest. 2002;122:293-298.
17. Chlap Z, Czarnobilska E, Kopinski P et al. Cytoimmunological atlas of bronchoalveolar lavage (BAL). Ed. Medycyna Praktyczna, Krakow 2000.
18. Sarcoidosis. Ed. by Drent M, Costabel U. ERS Monographs 2005; Vol. 10, 32.
19. Selman M, Thannicka VJ, Prado A. Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs. 2004;64:405-430.
20. Kopinski P, Sladek K, Szczeklik J et al. Expression of insulinlike growth factor-I (IGF-I) in the lower airways immune cells. Evaluation of its possible role as an antiapoptotic agent. Folia Histochem Cytobiol. 2006;44:249-258.
21. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001: Am J Respir Crit Care Med. 2002;165:277-304.
22. Klech H, Pohl W. Technical recommendations and guidelines for bronchoalveolar lavage (BAL). Eur Resp J. 1989;2:561-585.
23. Kopinski P, Szczeklik J, Lackowska B et al. Flow cytometric characteristics of alveolar lymphocytes obtained by bronchoalveolar lavage (BAL) in the control group - proposal of normal value range of AL subsets in nonsmokers. Central Eur J Immunol. 2004;29:63-72.
24. Domagala-Kulawik J, Hoser G, Kopinski P et al. Flow cytometric evaluation of lymphocyte subpopulations in BALF of cigarette smoking healthy persons. Folia Histochem Cytobiol. 1999;37:25-30.
25. Kopinski P, Szczeklik J, Balicka-Slusarczyk B et al. Modifications of the cytoimmunological pattern of bronchoalveolar lavage (BAL) material caused by cigarette smoking in selected lower air-way diseases [In Polish]. Przegl Lek. 2010; 67:866-870.
26. Seitz DH, Perl M, Mangold S et al. Pulmonary contusion induces alveolar type 2 epithelial cell apoptosis: role of alveolar macrophages and neutrophils. Shock. 2008;30:537-44.
27. Dupont PJ, Warrens AN. Fas ligand exerts its pro-inflammatory effects via neutrophil recruitment but not activation. Immunology. 2006;120:133-139.
28. Chorostowska-Wynimko J, Lesniewska-Radomska D, Krychniak-Soszka A et al. Cellular components of bronchoalveolar lavage correlate with lung function impairment and extrapulmonary involvement markers in active sarcoidosis. J Physiol Pharmac. 2004;55,3:41-47.
29. Wortinger MA, Foley JW, Larocque P et al. Fas ligand-induced murine pulmonary inflammation is reduced by a stable decoy receptor 3 analogue. Immunology. 2003;110:225-233.
30. Chung CS, Song GY, Lomas J, Simms HH et al. Inhibition of Fas/Fas ligand signaling improves septic survival: differential effects on macrophage apoptotic and functional capacity. J Leukoc Biol. 2003;74:344-51.